Sepracor estimates raised by Smith Barney

Sepracor Inc. was reiterated by Smith Barney Citigroup analyst Andrew Swanson at a hold rating with a target price of $70 for the stock. However, the firm raised its revenue estimates for second quarter to $62 million from $45 million and EPS loss to 50 cents from 66 cents. For 2005, Smith Barney raised its revenue estimate to $220 million from $170 million and EPS loss of 97 cents from $1.32. Sepracor, based in Marlborough, Mass., focuses on two therapeutic areas - respiratory and central nervous system disorders. Sepracor shares Friday gained $1.22, or 2.08%, to $59.98 on volume of 2.7 million shares versus the three-month running average of 1.7 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.